ucb_logo_pole2

US court rules in favour of UCB in patent dispute, shares jump

pharmafile | August 16, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing UCB, lacosamide, patent, vimpat 

UCB has received a major boost after a Delaware district court confirmed the validity of the company’s patents on one of its major drugs, the anti-seizure drug Vimpat (lacosamide).

The court decision is excellent news for UCB, with Vimpat expected to generate peak sales of more than €1.2 billion by 2020, according to its recent annual report. Along with other UCB drugs Cimzia, Neupro and Keppra, Vimpat accounts for almost 80% of the company’s net global sales.

UCB had brought generic drug companies, including Actavis, to court over applications to produce copies of Vimpat. The court’s favourable decision for UCB now guarantees patent protection to 2022.

Advertisement

The decision resulted in UCB’s largest one day share price spike in seven years, rising almost 10% to €75.28.

Anna Richo, executive vice president and general counsel for UCB, says: “We are pleased with Delaware chief judge Stark’s decision. This confirms the strength of our intellectual property for Vimpat.”

Sean Murray

Related Content

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder

UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis

UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …

Rare and severe epilepsies – current treatments and advance therapeutics

The current forms of immunotherapy, how T cell therapy works and what the future holds

The Gateway to Local Adoption Series

Latest content